Recovering from Covid: The 2021 Clinical Research Market

An overview of trends in the industry covering 2018, 2019, 2020 and 2021

The Covid-19 pandemic that began in 2020 had a devastating effect on our health as well as the global economy. The impact on the clinical research industry, in particular, is complex. On the one hand, the development of new vaccines and treatments gave a huge boost to research in two therapeutic areas. On the other, global lockdowns and the severity of cases meant clinical trials had to adapt quickly or be put on pause.  

We followed the clinical research market trends over the course of almost 4 years – 2018, 2019, 2020 and the first quarter of 2021. Our goal was to create a high-level overview of the clinical research landscape before and after the 2020 Covid-19 crisis. Though the pandemic is still far from over, there are some observations to be made already about the way the market is recovering in a more stabilized climate.  

Recovering from Covid: The 2021 Clinical Research Market gives an overview of how the therapeutic areas (TAs) and geographical regions (GRs) were doing before and during the rough 2020 – and how they are coping now, in 2021 when paused trials are resuming. 

Inside you will find:

Top TAs growing
Top GRs growing
before Covid
Top TAs least affected
by the pandemic
The impact of Covid-19
on GRs in 2020 and
2021 Q1
How TAs and GRs
were doing in
2021 Q1

To keep you up to speed with the dynamic landscape of the industry, we update the whitepaper quarterly and add more data as it becomes available.  

All data is taken from TrialHub – our feasibility intelligence platform that aggregates thousands of data sources in real-time and combines them with the insights of 100+ local experts. If you need help navigating the 2021 clinical research landscape, reach out to our team for support.

Scroll to Top